Retatrutide: The Triple Agonist GLP-1 That Outperforms Everything

Retatrutide achieved 28.7% weight loss in Phase 3 trials — the highest ever recorded. Here's how the GLP-1/GIP/glucagon triple agonist works, what the data shows, and when it could reach patients.

Read more

Support ✨
📞 Call
Hi there! Want to chat via voice? Click the Call button! 😊
🤖
Listening...
Speak naturally with the agent
📞